title: Soluble CD23 and interleukin-1 receptor antagonist in human asthmatics following antigen challenge.
abstract: Two postulated intrinsic anti-inflammatory mechanisms in asthma include the low affinity IgE receptor, or CD23, and interleukin 1 receptor antagonist (IL-1ra). We investigated the role these mediators play in the asthmatic response by measuring local levels in human asthmatics before and after segmental allergen challenge and examined the effect of inhaled corticosteroids on soluble CD23 and IL-1ra levels. Ten subjects underwent bronchoscopy at baseline and 24 hours after antigen challenge. Prior to challenge and every 12 hours afterward subjects received beclomethasone 252 microg or placebo. Fluid was analyzed for sCD23 and IL-1ra using ELISA immunoassays. Eosinophil percentages significantly increased at 24 hours following antigen challenge. sCD23 levels were generally undetectable at baseline and increased significantly following antigen challenge. IL-1ra levels increased 28-fold in the late-phase response. Beclomethasone significantly reduced the late-phase eosinophil percentage at 24 hours compared with placebo but did not attenuate late-phase sCD23 or IL-1ra levels. Our data showed a significant rise in the levels of two mediators thought to play an important role in the attenuation of the asthmatic response. The finding that steroid treatment did not enhance these levels suggests that this may be an independent approach to asthma therapy that should be investigated.
authors.affiliation: Vanderbilt University, Nashville, Tennessee, USA. damrol@gw.mp.sc.edu
authors.forename: David J
authors.initials: DJ
authors.lastname: Amrol
authors.forename: David D
authors.initials: DD
authors.lastname: Hagaman
authors.forename: James R
authors.initials: JR
authors.lastname: Sheller
authors.forename: John J
authors.initials: JJ
authors.lastname: Murray
mesh_terms: D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D001249:Asthma / Q000175:diagnosis / Q000276:immunology*; D001507:Beclomethasone / Q000494:pharmacology; D001985:Bronchial Provocation Tests; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004797:Enzyme-Linked Immunosorbent Assay; D004804:Eosinophils / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017455:Receptors, IgE / Q000096:biosynthesis*; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors* / Q000096:biosynthesis
chemical_list: D000893:Anti-Inflammatory Agents; D017455:Receptors, IgE; D017472:Receptors, Interleukin-1; D001507:Beclomethasone